Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical PlatformBusiness Wire • 02/26/24
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)Business Wire • 02/23/24
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLCBusiness Wire • 02/14/24
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTXBusiness Wire • 02/14/24
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid TumorsBusiness Wire • 02/14/24
VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial IntelligenceBusiness Wire • 02/13/24
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting PeriodBusiness Wire • 02/12/24
J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemenMarket Watch • 02/08/24
Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch ForForbes • 02/08/24
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricingCNBC • 02/08/24